Forest,Paion end stroke collaboration
Forest Laboratories and Paion GMBH (developing drugs for stroke and other thrombotic diseases) will jointly develop and market, in the US and Canada, Paion's ischemic stroke candidate desmoteplase, a Phase II plasminogen activator (a blood clot-dissolving agent) that was recently granted fast-track status for an expedited FDA review.
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com